J82Homo sapiens (Human)Cancer cell line
Also known as: J-82, J 82, J82COT, J82 COT, J82 CO'T, J82/WT
Quick Overview
Human bladder cancer cell line for research on tumor biology and drug testing.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0359 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Urinary bladder[UBERON:UBERON_0001255] |
Donor Information
| Age | 58 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Bladder carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Bladder Urothelial Carcinoma |
| OncoTree Code | BLCA |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000396_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | APC | p.Ser770Pro (c.2308T>C) | Heterozygous | - | from parent cell line J82 |
| MutationSimple | PIK3CA | p.Pro124Leu (c.371C>T) | Heterozygous | - | from parent cell line J82 |
| MutationSimple | PTEN | p.Asn212fs*1 (c.635_1212del578) | Homozygous | - | from parent cell line J82 |
| MutationSimple | RB1 | c.2107-2A>G | Homozygous | Splice acceptor mutation | from parent cell line J82 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | TP53 | p.Glu271Lys (c.811G>A) | Heterozygous | - | Unknown |
| MutationSimple | TP53 | p.Lys320Asn (c.960G>C) | Heterozygous | - | from parent cell line J82 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue Antigens 11:279-286(1978).
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Fogh J.
Natl. Cancer Inst. Monogr. 49:5-9(1978).
Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma.
O'Toole C.M., Price Z.H., Ohnuki Y., Unsgaard B.
Br. J. Cancer 38:64-76(1978).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.
Marshall C.J., Franks L.M., Carbonell A.W.
J. Natl. Cancer Inst. 58:1743-1751(1977).
Alkaline phosphatase activity in human bladder tumor cell lines.";
Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.
J. Histochem. Cytochem. 25:266-274(1977).
Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.
Little J.B., McConkie-Rosell A., Buckley E.G., Dryja T.P.
N. Engl. J. Med. 321:1689-1695(1989).
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Pereira-Smith O.M., Smith J.R.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Franks L.M.
Cancer Res. 46:3630-3636(1986).
Growth of a malignant human urothelial cell line (J82) in a serum-free medium (HMRI-1) developed previously for normal human urothelium.
Bishai M.B., Kagawa S., Narayan K.S., Jones L.W., Kirk D.
J. Urol. 134:1287-1290(1985).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Identity of some human bladder cancer cell lines.";
O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.
Nature 301:429-430(1983).
p53 mutations in bladder carcinoma cell lines.";
Lippa M., Hatzivassiliou G., Tan J.
Oncol. Res. 6:569-579(1994).
Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
Xu B.H., Gupta V., Singh S.V.
Int. J. Cancer 58:686-692(1994).
Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a navelbine-resistant bladder carcinoma cell line.
Debal V., Breillout F., Manfait M.
Anticancer Res. 17:1147-1154(1997).
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
Markl I.D.C., Jones P.A.
Cancer Res. 58:5348-5353(1998).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines.
Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.
Genes Chromosomes Cancer 34:86-96(2002).
Novel chromosome findings in bladder cancer cell lines detected with multiplex fluorescence in situ hybridization.
Young B.D., Oliver R.T.D.
Cancer Genet. Cytogenet. 135:139-146(2002).
High-resolution analysis of DNA copy number using oligonucleotide microarrays.
Weber B., Shapero M.H., Wooster R.
Genome Res. 14:287-295(2004).
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Knowles M.A.
Genes Chromosomes Cancer 43:315-328(2005).
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Carrato A., Tardon A., Serra C., Real F.X.
Cancer Res. 66:7401-7404(2006).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Kwiatkowski D.J.
J. Pathol. 230:17-27(2013).
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Hurst C.D., Platt F.M., Knowles M.A.
Eur. Urol. 65:367-369(2014).
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Knowles M.A.
PLoS ONE 8:E84411-E84411(2013).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).